Basic Information
RNALocate ID: | RLID:01001256 |
RNA Symbol: | hsa-miR-16-5p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-16 |
RNA ID: | miRBase:MIMAT0000069 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21695135 |
Tissue/Cell Line: | Cell line (HeLa) |
Method: | Microarray |
Heatmap showing the 57 miRNAs differentially expressed in HeLa cells from mitochondrial and cytosolic RNA. Three independent microarray profiling experiments (microarray n1, n2 and n3) are shown and reproducibly revealed 13 miRNAs enriched in mitochondrial RNA. Originally published in PLoS One. Bandiera S, et al, 2011. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | While 44 miRNAs showed a greater enrichment in the cytosolic Hy3-labeled RNA fraction, 13 miRNAs were significantly and reproducibly enriched in the mitochondrial Hy5-labeled RNA sample (ranging from 1.5- to 56-fold), namely hsa-miR-1973, hsa-miR-1275, hsa-miR-494, hsa-miR-513a-5p, hsa-miR-1246, hsa-miR-328, hsa-miR-1908, hsa-miR-1972, hsa-miR-1974, hsa-miR-1977, hsa-miR-638, hsa-miR-1978 and hsa-miR-1201 (Figure 5A). Data are collected from Figure 5. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001255 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001257 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001258 | Mitochondrion | Osteosarcoma cell line (143B) | 27396686 |
RLID:01001259 | Mitochondrion | Osteosarcoma cell line (143B) | 27563705 |
RLID:01001260 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001261 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001262 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001263 | Nucleus | GC cell line (MGC-803) | 29872807 |
RLID:01001264 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001265 | Nucleus | Neural progenitor cells | 21363885 |
RLID:01001266 | Polysome | Human cervical cancer cell line (HeLa) | 25609084 |
RLID:11000667 | Exosome | Pooled sera | 27278097 |
RLID:11000668 | Exosome | EBV- and KSHV-negative Burkitt lymphoma cell line (Bjab)|EBV-infected lymphoblastoid cell line (LCL)|KSHV-infected lymphoma cell lines (BCBL-1|TY-1) | 27611973 |
RLID:11000669 | Exosome | Plasma | 30154547 |
RLID:11000670 | Exosome | Glioblastoma cells | 19011622 |
RLID:11000671 | Exosome | Human embryonic kidney cell line (HEK-293) | 20353945 |
RLID:11000672 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
RLID:11000673 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11000674 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000675 | Exosome | Brain tissue | 23382797 |
RLID:11000676 | Exosome | Plasma | 23663360 |
RLID:11000677 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000678 | Exosome | Plasma | 24130905 |
RLID:11000679 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
RLID:11000680 | Extracellular Vesicle | Plasma | 28588009 |
RLID:11000681 | Microvesicle | Glioblastoma cells | 19011622 |
RLID:11000682 | Microvesicle | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
RLID:11000683 | Microvesicle | Plasma | 23077538 |
RLID:11000684 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000685 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000008 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
RLID-D:11000268 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-16-5p | Alk+ anaplastic large-cell lymphoma | MNDR-E-MI-18717 |
MNDR | hsa-miR-16-5p | Mantle cell lymphoma | MNDR-E-MI-18718 |
MNDR | hsa-miR-16-5p | Splenic marginal zone lymphoma | MNDR-E-MI-18719 |
MNDR | hsa-miR-16-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-18720 |
MNDR | hsa-miR-16-5p | Oral squamous cell carcinoma | MNDR-E-MI-18721 |
MNDR | hsa-miR-16-5p | Medulloblastoma | MNDR-E-MI-18722 |
MNDR | hsa-miR-16-5p | B cell lymphoma of malt type | MNDR-E-MI-18723 |
MNDR | hsa-miR-16-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-18724 |
MNDR | hsa-miR-16-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-18725 |
MNDR | hsa-miR-16-5p | Lymphoma | MNDR-E-MI-18726 |
MNDR | hsa-miR-16-5p | Lymphoma non-hodgkin | MNDR-E-MI-18727 |
MNDR | hsa-miR-16-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-18728 |
MNDR | hsa-miR-16-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-18729 |
MNDR | hsa-miR-16-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-18730 |
MNDR | hsa-miR-16-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-18731 |
MNDR | hsa-miR-16-5p | Her2-receptor positive breast cancer | MNDR-E-MI-18732 |
MNDR | hsa-miR-16-5p | Breast cancer luminal | MNDR-E-MI-18733 |
MNDR | hsa-miR-16-5p | Niemann-pick disease type c | MNDR-E-MI-18734 |
MNDR | hsa-miR-16-5p | Prostate cancer | MNDR-E-MI-18735 |
MNDR | hsa-miR-16-5p | B-cell chronic lymphocytic leukemia | MNDR-E-MI-18736 |
MNDR | hsa-miR-16-5p | Gastric cancer | MNDR-E-MI-18737 |
MNDR | hsa-miR-16-5p | Gastric lymphoma | MNDR-E-MI-18738 |
MNDR | hsa-miR-16-5p | Alzheimer disease | MNDR-E-MI-18739 |
MNDR | hsa-miR-16-5p | Intracranial aneurysm | MNDR-E-MI-18740 |
MNDR | hsa-miR-16-5p | Dysautonomia familial | MNDR-E-MI-18741 |
MNDR | hsa-miR-16-5p | Malaria | MNDR-E-MI-18742 |
MNDR | hsa-miR-16-5p | Ataxia telangiectasia | MNDR-E-MI-18743 |
MNDR | hsa-miR-16-5p | Huntington disease | MNDR-E-MI-18744 |
MNDR | hsa-miR-16-5p | Chorea | MNDR-E-MI-18745 |
MNDR | hsa-miR-16-5p | Cardiovascular disease | MNDR-E-MI-18746 |
MNDR | hsa-miR-16-5p | Moyamoya disease | MNDR-E-MI-18747 |
MNDR | hsa-miR-16-5p | Lung cancer | MNDR-E-MI-18748 |
MNDR | hsa-miR-16-5p | Down syndrome | MNDR-E-MI-18749 |
MNDR | hsa-miR-16-5p | Parkinson disease | MNDR-E-MI-18750 |
MNDR | hsa-miR-16-5p | Niemann-pick disease | MNDR-E-MI-18751 |
MNDR | hsa-miR-16-5p | Basal-like breast cancer | MNDR-E-MI-18752 |
MNDR | hsa-miR-16-5p | Cancer | MNDR-E-MI-18753 |
MNDR | hsa-miR-16-5p | Pituitary neoplasms | MNDR-E-MI-18754 |
MNDR | hsa-miR-16-5p | Pancreatic cancer | MNDR-E-MI-18755 |
MNDR | hsa-miR-16-5p | Melanoma | MNDR-E-MI-18756 |
MNDR | hsa-miR-16-5p | Gaucher disease | MNDR-E-MI-18757 |
MNDR | hsa-miR-16-5p | Rectum adenocarcinoma | MNDR-E-MI-18758 |
MNDR | hsa-miR-16-5p | Colon cancer | MNDR-E-MI-18759 |
MNDR | hsa-miR-16-5p | Ischemic attack transient | MNDR-E-MI-18760 |
MNDR | hsa-miR-16-5p | Colon adenocarcinoma | MNDR-E-MI-18761 |
MNDR | hsa-miR-16-5p | Multiple sclerosis | MNDR-E-MI-18762 |
MNDR | hsa-miR-16-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-18763 |
MNDR | hsa-miR-16-5p | Familial ovarian cancer | MNDR-E-MI-18764 |
MNDR | hsa-miR-16-5p | Laryngeal carcinoma | MNDR-E-MI-18765 |
MNDR | hsa-miR-16-5p | Carcinoma ductal breast | MNDR-E-MI-18766 |
MNDR | hsa-miR-16-5p | Glioblastoma | MNDR-E-MI-18767 |
MNDR | hsa-miR-16-5p | Astrocytoma | MNDR-E-MI-18768 |
MNDR | hsa-miR-16-5p | Glioma | MNDR-E-MI-18769 |
MNDR | hsa-miR-16-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-18770 |
MNDR | hsa-miR-16-5p | Oligodendroglioma | MNDR-E-MI-18771 |
MNDR | hsa-miR-16-5p | Chordoma | MNDR-E-MI-18772 |
MNDR | hsa-miR-16-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-18773 |
MNDR | hsa-miR-16-5p | Epilepsy temporal lobe | MNDR-E-MI-18774 |
MNDR | hsa-miR-16-5p | Osteosarcoma | MNDR-E-MI-18775 |
MNDR | hsa-miR-16-5p | Liposarcoma | MNDR-E-MI-18776 |
MNDR | hsa-miR-16-5p | Coronary artery disease | MNDR-E-MI-18777 |
MNDR | hsa-miR-16-5p | Breast carcinoma | MNDR-E-MI-18778 |
MNDR | hsa-miR-16-5p | Infarction middle cerebral artery | MNDR-E-MI-18779 |
MNDR | hsa-miR-16-5p | Cerebral infarction | MNDR-E-MI-18780 |
MNDR | hsa-miR-16-5p | Liver cancer | MNDR-E-MI-18781 |
MNDR | hsa-miR-16-5p | Cervical adenocarcinoma | MNDR-E-MI-18782 |
MNDR | hsa-miR-16-5p | Gastric adenocarcinoma | MNDR-E-MI-18783 |
MNDR | hsa-miR-16-5p | Cervical squamous cell carcinoma | MNDR-E-MI-18784 |
MNDR | hsa-miR-16-5p | Pituitary adenoma | MNDR-E-MI-18785 |
MNDR | hsa-miR-16-5p | Lung squamous cell carcinoma | MNDR-E-MI-18786 |
MNDR | hsa-miR-16-5p | Carcinoma lung non small cell | MNDR-E-MI-18787 |
MNDR | hsa-miR-16-5p | Adrenocortical cancer | MNDR-E-MI-18788 |
MNDR | hsa-miR-16-5p | Thyroid carcinoma | MNDR-E-MI-18789 |
MNDR | hsa-miR-16-5p | Papillary thyroid carcinoma | MNDR-E-MI-18790 |
MNDR | hsa-miR-16-5p | Ovarian carcinoma | MNDR-E-MI-18791 |
MNDR | hsa-miR-16-5p | Bladder urothelial carcinoma | MNDR-E-MI-18792 |
MNDR | hsa-miR-16-5p | Pancreatic adenocarcinoma | MNDR-E-MI-18793 |
MNDR | hsa-miR-16-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-18794 |
MNDR | hsa-miR-16-5p | Carcinoma renal cell | MNDR-E-MI-18795 |
MNDR | hsa-miR-16-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-18796 |
MNDR | hsa-miR-16-5p | Clear cell renal cell carcinoma | MNDR-E-MI-18797 |
MNDR | hsa-miR-16-5p | Biliary tract cancer | MNDR-E-MI-18798 |
MNDR | hsa-miR-16-5p | Cholangiocarcinoma | MNDR-E-MI-18799 |
MNDR | hsa-miR-16-5p | Esophageal cancer | MNDR-E-MI-18800 |
MNDR | hsa-miR-16-5p | Lung small cell carcinoma | MNDR-E-MI-18801 |
MNDR | hsa-miR-16-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-18802 |
MNDR | hsa-miR-16-5p | Testicular germ cell cancer | MNDR-E-MI-18803 |
MNDR | hsa-miR-16-5p | Heart failure | MNDR-E-MI-18804 |
MNDR | hsa-miR-16-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-18805 |
MNDR | hsa-miR-16-5p | Breast invasive carcinoma | MNDR-E-MI-18806 |
MNDR | hsa-miR-16-5p | Juvenile rheumatoid arthritis | MNDR-E-MI-18807 |
MNDR | hsa-miR-16-5p | Hepatocellular carcinoma | MNDR-E-MI-18808 |
MNDR | hsa-miR-16-5p | Familiar ovarian carcinoma | MNDR-E-MI-18809 |
MNDR | hsa-miR-16-5p | B-cell lymphoma | MNDR-E-MI-18810 |
MNDR | hsa-miR-16-5p | Rheumatoid arthritis | MNDR-E-MI-18811 |
MNDR | hsa-miR-16-5p | T-cell leukemia | MNDR-E-MI-18812 |
MNDR | hsa-miR-16-5p | Neuroblastoma | MNDR-E-MI-18813 |
MNDR | hsa-miR-16-5p | Osteoarthritis | MNDR-E-MI-18814 |
MNDR | hsa-miR-16-5p | Hodgkin lymphoma | MNDR-E-MI-18815 |
MNDR | hsa-miR-16-5p | Ulcerative colitis | MNDR-E-MI-18816 |
MNDR | hsa-miR-16-5p | Burkitt lymphoma | MNDR-E-MI-18817 |
MNDR | hsa-miR-16-5p | Crohn disease | MNDR-E-MI-18818 |
MNDR | hsa-miR-16-5p | Neuromyelitis optica | MNDR-E-MI-18819 |
MNDR | hsa-miR-16-5p | Skin cutaneous melanoma | MNDR-E-MI-18820 |
MNDR | hsa-miR-16-5p | Skin melanoma | MNDR-E-MI-18821 |
MNDR | hsa-miR-16-5p | Acute myelogenous leukemia | MNDR-E-MI-18822 |
MNDR | hsa-miR-16-5p | Colorectal cancer | MNDR-E-MI-18823 |
MNDR | hsa-miR-16-5p | Type 2 diabetes mellitus | MNDR-E-MI-18824 |
MNDR | hsa-miR-16-5p | Multiple myeloma | MNDR-E-MI-18825 |
MNDR | hsa-miR-16-5p | Serous ovarian cancer | MNDR-E-MI-18826 |
MNDR | hsa-miR-16-5p | Ependymoma | MNDR-E-MI-18827 |
MNDR | hsa-miR-16-5p | Hearing loss noise-induced | MNDR-E-MI-18828 |
MNDR | hsa-miR-16-5p | Nasopharyngeal cancer | MNDR-E-MI-18829 |
MNDR | hsa-miR-16-5p | Prostatic neoplasms | MNDR-E-MI-18830 |
MNDR | hsa-miR-16-5p | Pseudorabies | MNDR-E-MI-18831 |
MNDR | hsa-miR-16-5p | Sleep deprivation | MNDR-E-MI-18832 |
MNDR | hsa-miR-16-5p | Hypersomnolence idiopathic | MNDR-E-MI-18833 |
MNDR | hsa-miR-16-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-18834 |
MNDR | hsa-miR-16-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-18835 |
MNDR | hsa-miR-16-5p | Pituitary acth hypersecretion | MNDR-E-MI-18836 |
MNDR | hsa-miR-16-5p | Stroke lacunar | MNDR-E-MI-18837 |
MNDR | hsa-miR-16-5p | Breast cancer her3+ negative | MNDR-E-MI-18838 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCB1 | Homo sapiens | RR00022775 |
TOP